Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
Dalby M, Montalescot G, Bal dit Sollier C, Vicaut E, Soulat T, Collet JP, Choussat R, Gallois V, Drobinski G, Drouet L, Thomas D. Dalby M, et al. Among authors: gallois v. J Am Coll Cardiol. 2004 Jan 21;43(2):162-8. doi: 10.1016/j.jacc.2003.08.033. J Am Coll Cardiol. 2004. PMID: 14736431 Free article. Clinical Trial.
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthélémy O, Beygui F, Gallois V, Montalescot G; CLOVIS-2 Investigators. Collet JP, et al. Among authors: gallois v. JACC Cardiovasc Interv. 2011 Apr;4(4):392-402. doi: 10.1016/j.jcin.2011.03.002. JACC Cardiovasc Interv. 2011. PMID: 21511218 Free article. Clinical Trial.
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.
Collet JP, Hulot JS, Abtan J, Anzaha G, Kerneis M, Silvain J, Cayla G, O'Connor SA, Barthélémy O, Beygui F, Galier S, Brugier D, Stanek EJ, Charland SL, Gallois V, Montalescot G; DOSAPI investigators. Collet JP, et al. Among authors: gallois v. Eur J Clin Pharmacol. 2014 Sep;70(9):1049-57. doi: 10.1007/s00228-014-1710-1. Epub 2014 Jul 12. Eur J Clin Pharmacol. 2014. PMID: 25012577 Clinical Trial.
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.
Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL Investigators. Montalescot G, et al. Lancet. 2011 Aug 20;378(9792):693-703. doi: 10.1016/S0140-6736(11)60876-3. Lancet. 2011. PMID: 21856483 Clinical Trial.
The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes.
Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KA, Goldberg RJ, Anderson FA Jr; Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators. Goodman SG, et al. Am Heart J. 2009 Aug;158(2):193-201.e1-5. doi: 10.1016/j.ahj.2009.06.003. Am Heart J. 2009. PMID: 19619694
12 results